Study Finds Teenage Boys Six Times More Likely To Suffer Heart Problems From Vaccine Than Be Hospitalized by COVID

Authors; Paul Joseph Watson via Summit News,

Research conducted by the University of California has found that teenage boys are six times more likely to suffer from heart problems caused by the COVID-19 vaccine than to be hospitalized as a result of COVID-19 itself.

“A team led by Dr Tracy Hoeg at the University of California investigated the rate of cardiac myocarditis – heart inflammation – and chest pain in children aged 12-17 following their second dose of the vaccine,” reports the Telegraph.

“They then compared this with the likelihood of children needing hospital treatment owing to Covid-19, at times of low, moderate and high rates of hospitalisation.”

Researchers found that the risk of heart complications for boys aged 12-15 following the vaccine was 162.2 per million, which was the highest out of all the groups they looked at.

This compares to the risk of a healthy boy being hospitalized as a result of a COVID infection, which is around 26.7 per million, meaning the risk they face from the vaccine is 6.1 times higher.

Even during high risk rates of COVID, such as in January this year, the threat posed by the vaccine is 4.3 times higher, while during low risk rates, the risk of teenage boys suffering a “cardiac adverse event” from the vaccine is a whopping 22.8 times higher.

The research data was based on a study of adverse reactions suffered by teens between January and June this year.

In a sane world, such data should represent the nail in the coffin for the argument that teenagers and children should be mandated to take the coronavirus vaccine, but it obviously won’t.

In the UK, the government is pushing to vaccinate 12-15-year-olds, even without parental consent, despite the Joint Committee on Vaccination and Immunisation (JCVI) advising against it.

Meanwhile, in America, Los Angeles County school officials voted unanimously to mandate COVID shots for all

U.S. probing Moderna vaccine for higher heart inflammation risk – Washington Post

Authors: Reporting by Shubham Kalia in Bengaluru; Editing by Krishna Chandra Eluri and Ramakrishnan M.

Aug 19 (Reuters) – U.S. health officials are investigating reports that Moderna Inc’s (MRNA.O) COVID-19 vaccine may be linked to a higher risk of a rare heart condition in younger adults than previously thought, the Washington Post reported late on Thursday, citing people familiar with the review.

The report quoted a source saying it was too early for the regulators to reach a conclusion, and that additional work was needed before any recommendation was made.

Health regulators in June had added a warning to the literature that accompanies the mRNA vaccines produced by Moderna and Pfizer to flag the rare risk of heart inflammation seen primarily in young males. However, they said the benefit of the shots in preventing COVID-19 continued to outweigh the risks. read more

There might be a 2.5 times higher incidence of myocarditis in those who get the Moderna vaccine compared with Pfizer’s vaccine, the Post quoted a source as saying.

The investigation that is focused on Canadian data suggests that risks of myocarditis might especially be higher for males below the age of 30 or so, according to the report.

Moderna and the U.S. Food and Drug Administration (FDA) did not immediately respond to Reuters’ requests for comment.

Troponin and BNP Use in COVID-19

Mar 18, 2020 Cardiology Magazine

Authors: James L. Januzzi Jr., MD, FACC

  1. What are the potential mechanisms underlying troponin elevation with COVID-19 infection? Rise and/or fall of troponin indicating myocardial injury is common among patients with acute respiratory infections and correlated with disease severity.  Abnormal troponin values are common among those with COVID-19 infection particularly when testing with a high sensitivity cardiac troponin (hs-cTn) assay. In a recent article summarizing clinical course of patients with COVID-19, detectable hs-cTnI was observed in most patients, and hs-cTnI was significantly elevated in more than half of the patients that died. The mechanisms explaining myocardial injury in those with COVID-19 infection are not fully understood, however in keeping with other severe respiratory illnesses, direct (“non-coronary”) myocardial damage is almost certainly the most common cause. Given presence of abundant distribution of ACE2 – the binding site for the SARS-CoV-2 – in cardiomyocytes, some have postulated that myocarditis might explain rise of hs-cTn in some cases, particularly as acute left ventricular failure has been described in some cases. Lastly, acute myocardial infarction (MI) – either Type 1 MI based plaque rupture triggered by the infection, or Type 2 MI based on supply-demand inequity – is always possible. Importantly, a rise and/or fall of hs-cTn is not sufficient to secure the diagnosis of acute MI, which should be based on clinical judgment, symptoms/signs, and ECG changes. Given the frequency and non-specific nature of abnormal troponin results among patients with COVID-19 infection, clinicians are advised to only measure troponin if the diagnosis of acute MI is being considered on clinical grounds and an abnormal troponin should not be considered evidence for an acute MI without corroborating evidence.
  2. What are the potential mechanisms underlying elevation of natriuretic peptides with COVID-19 infection? Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses typically in the absence of elevated filling pressures or clinical heart failure. Much like troponin, elevation of BNP or NT-proBNP is associated with an unfavorable course among patients with ARDS. Patients with COVID-19 often demonstrate significant elevation of BNP or NT-proBNP. The significance of this finding is uncertain and should not necessarily trigger an evaluation or treatment for heart failure unless there is clear clinical evidence for the diagnosis.
  3. What testing should be performed in COVID-19 patients with acute myocardial injury or abnormal natriuretic peptide results?

For More Information: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19

US case series study in children study looking at association of myocarditis with the Pfizer-BioNTech COVID-19 vaccine

Authors: byUK Science Media Centre|Published onAugust 10, 2021: Prof Peter Openshaw

In this case series, 15 cases of myocarditis are described from a single paediatric referral centre in May, June and July 2021.  Each had been given the Pfizer mRNA vaccine between 1 and 6 days prior to diagnosis; children were aged 12-18 years.  In addition to chest pain, most had fever and muscle pain with evidence of inflammation of the heart muscle evident on tests.  All cases were relatively mild and most resolved completely without treatment.  All but one case was male, and most were after the 2nd dose.

The problem with case series of this type is the lack of comparison groups.  How many cases of myocarditis might be seen in normal children, or those given other vaccines (including those that are not for COVID), or in teenagers infected with SARS-CoV-2?

As the authors note, myocarditis does happen after other vaccines.  The estimated rate (62.8 cases per million) makes this a rare event.  To put this in context, the authors point out that COVID-19 vaccination in males aged 12 to 29 years would prevent 11,000 COVID-19 cases, 560 hospitalizations, 138 intensive care unit admissions and 6 deaths compared with 39 to 47 expected case of myocarditis, if the link with the vaccine is causal.

In another recent study that has not yet been peer-reviewed (https://www.medrxiv.org/content/10.1101/2021.07.23.21260998v1), the authors estimated that males aged 12 to 17 were most likely to develop myocarditis within three months of catching covid-19, at a rate of about 450 cases per million infections.  Mendel Singer at Case Western Reserve University in Ohio (an author on this study) said: “If you’re focused on heart inflammation, the safer bet is to take the vaccine.”  The calculations on which this statement is based are still under discussion, but my view that teenagers should be considered for vaccination is not changed by this new publication.

For More Information: https://covidvaccinehub.org/articles/us-case-series-study-in-children-study-looking-at-association-of-myocarditis-with-the-pfizer-biontech-covid-19-vaccine